Novan to Report Third Quarter 2021 Financial Results on November 10, 2021
Novan, Inc. (NASDAQ: NOVN) will report its Q3 2021 financial results on November 10, 2021, followed by a conference call at 8:30 a.m. ET. The call, led by President and CEO Paula Brown Stafford, will provide insights into the company’s operational and financial performance. Participants can join by dialing (844) 707-0661 (domestic) or (703) 318-2240 (international), referencing conference ID: 1142988. The live audio webcast will be available on the Novan website and archived for 90 days.
- Upcoming Q3 2021 earnings report on November 10, 2021.
- Live audio webcast for investors to access financial insights.
- None.
Company to host conference call and webcast on Wednesday, November 10, 2021, at 8:30 a.m. ET
DURHAM, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2021 financial results on Wednesday, November 10th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.
The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (844) 707-0661 (domestic) or (703) 318-2240 (international) and referencing conference ID: 1142988. The live webcast will be accessible on the Events page of the Investors section of the Novan website, novan.com, and will be archived for 90 days.
About Novan
Novan, Inc. is a pre-commercial nitric oxide-based pharmaceutical company focused on dermatology and anti-infective therapies. We leverage our core synergies of science, capital, resources and patient needs to create value by bringing new nitric oxide-based medicines to market. Our goal is to create the world’s leader in nitric oxide-based science, technology, and clinical translation in support of delivering safe and efficacious therapies using our proprietary nitric oxide-based technology platform, NITRICIL™ to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications.
INVESTOR AND MEDIA CONTACT:
Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com
FAQ
What date will Novan report its Q3 2021 earnings?
What time is Novan's conference call for Q3 2021 results?
How can I access the live webcast for Novan's earnings call?
Who will host Novan's Q3 2021 earnings call?
What is the conference ID for Novan's Q3 2021 earnings call?
